We demonstrated this in the context of myelodysplastic syndromes (MDS), where mutations in splicing factors (SF) genes such as U2AF1 are prevalent in approximately 50% of patients66–68 and linked to decreased survival rates69–75. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.